share_log

Anika Therapeutics Analyst Ratings

Benzinga ·  Aug 14, 2023 20:44
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/14/2023 30.58% Barrington Research → $24 Upgrades Market Perform → Outperform
08/10/2023 25.14% Stephens & Co. $28 → $23 Maintains Equal-Weight
05/31/2023 52.34% Stephens & Co. → $28 Reiterates Equal-Weight → Equal-Weight
04/14/2023 52.34% Stephens & Co. → $28 Reiterates → Equal-Weight
03/07/2023 Barrington Research Downgrades Outperform → Market Perform
11/09/2022 68.66% Barrington Research → $31 Upgrades Market Perform → Outperform
10/14/2022 41.46% Stephens & Co. → $26 Reinstates → Equal-Weight
03/09/2022 Stephens & Co. Downgrades Overweight → Equal-Weight
11/16/2021 199.24% Stephens & Co. → $55 Initiates Coverage On → Overweight
07/16/2021 150.27% UBS → $46 Initiates Coverage On → Neutral
12/16/2020 133.95% Barrington Research → $43 Upgrades Market Perform → Outperform
01/21/2020 231.88% Sidoti & Co. → $61 Upgrades Neutral → Buy
11/05/2019 57.78% BWS Financial → $29 Initiates Coverage On → Sell
09/23/2019 First Analysis Downgrades Strong Buy → Outperform
02/22/2019 123.07% Sidoti & Co. $56 → $41 Downgrades Buy → Neutral

What is the target price for Anika Therapeutics (ANIK)?

The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on August 14, 2023. The analyst firm set a price target for $24.00 expecting ANIK to rise to within 12 months (a possible 30.58% upside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Anika Therapeutics (ANIK)?

The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.

When is the next analyst rating going to be posted or updated for Anika Therapeutics (ANIK)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.

Is the Analyst Rating Anika Therapeutics (ANIK) correct?

While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $24.00. The current price Anika Therapeutics (ANIK) is trading at is $18.38, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment